Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1804 2
1962 1
1966 1
1971 1
1972 2
1975 2
1976 2
1977 2
1978 3
1979 3
1980 2
1982 2
1983 1
1984 1
1985 2
1987 6
1988 12
1989 21
1990 22
1991 20
1992 30
1993 34
1994 21
1995 28
1996 21
1997 15
1998 24
1999 12
2000 23
2001 23
2002 18
2003 28
2004 30
2005 30
2006 32
2007 39
2008 52
2009 57
2010 76
2011 86
2012 100
2013 136
2014 161
2015 193
2016 238
2017 389
2018 525
2019 760
2020 1159
2021 1555
2022 1724
2023 1990
2024 2468
2025 2956
2026 242

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,916 results

Results by year

Filters applied: . Clear all
Page 1
Cellular senescence in ageing: from mechanisms to therapeutic opportunities.
Di Micco R, Krizhanovsky V, Baker D, d'Adda di Fagagna F. Di Micco R, et al. Nat Rev Mol Cell Biol. 2021 Feb;22(2):75-95. doi: 10.1038/s41580-020-00314-w. Epub 2020 Dec 16. Nat Rev Mol Cell Biol. 2021. PMID: 33328614 Free PMC article. Review.
Cellular senescence, first described in vitro in 1961, has become a focus for biotech companies that target it to ameliorate a variety of human conditions. Eminently characterized by a permanent proliferation arrest, cellular senescence occurs in response to endogenous and …
Cellular senescence, first described in vitro in 1961, has become a focus for biotech companies that target it to ameliorate a variet …
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF, Cordonnier C, Duarte RF, Florescu DF, Kamar N, Kumar D, Maertens J, Marty FM, Papanicolaou GA, Silveira FP, Witzke O, Wu J, Sundberg AK, Fournier M; SOLSTICE Trial Investigators. Avery RK, et al. Clin Infect Dis. 2022 Sep 10;75(4):690-701. doi: 10.1093/cid/ciab988. Clin Infect Dis. 2022. PMID: 34864943 Free PMC article. Clinical Trial.
Febrile Neutropenia.
Punnapuzha S, Edemobi PK, Elmoheen A. Punnapuzha S, et al. 2023 Mar 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Mar 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31082146 Free Books & Documents.
Neutropenic fever is when there is a single oral temperature greater than or equal to 101 F (38.3 C) or a temperature greater than or equal to 100.4 F (38 C) for at least an hour, with an absolute neutrophilic count (ANC) of less than 1500 cells/microliter. ...
Neutropenic fever is when there is a single oral temperature greater than or equal to 101 F (38.3 C) or a temperature greater than or …
In vivo chimeric antigen receptor (CAR)-T cell therapy.
Bot A, Scharenberg A, Friedman K, Guey L, Hofmeister R, Andorko JI, Klichinsky M, Neumann F, Shah JV, Swayer AJ, Trudeau K, Weissman D, Stephan MT, Buchholz CJ, June CH. Bot A, et al. Nat Rev Drug Discov. 2025 Sep 30. doi: 10.1038/s41573-025-01291-5. Online ahead of print. Nat Rev Drug Discov. 2025. PMID: 41028170 Review.
Physiology, Fever.
Balli S, Shumway KR, Sharan S. Balli S, et al. 2023 Sep 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Sep 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32966005 Free Books & Documents.
Low-grade: 37.3 to 38.0 C (99.1 to 100.4 F). Moderate-grade: 38.1 to 39.0 C (100.6 to 102.2 F). High-grade: 39.1 to 41 C (102.4 to 105.8 F). Hyperthermia: Greater than 41 C (105.8 F). It is essential to understand that the definition of fever is not th …
Low-grade: 37.3 to 38.0 C (99.1 to 100.4 F). Moderate-grade: 38.1 to 39.0 C (100.6 to 102.2 F). High-grade: 39.1 to 41 C (102. …
NAD+ in Brain Aging and Neurodegenerative Disorders.
Lautrup S, Sinclair DA, Mattson MP, Fang EF. Lautrup S, et al. Cell Metab. 2019 Oct 1;30(4):630-655. doi: 10.1016/j.cmet.2019.09.001. Cell Metab. 2019. PMID: 31577933 Free PMC article. Review.
Psoriasis.
Armstrong AW, Blauvelt A, Callis Duffin K, Huang YH, Savage LJ, Guo L, Merola JF. Armstrong AW, et al. Nat Rev Dis Primers. 2025 Jun 26;11(1):45. doi: 10.1038/s41572-025-00630-5. Nat Rev Dis Primers. 2025. PMID: 40571687 Review.
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Lee SM, Schulz C, Prabhash K, Kowalski D, Szczesna A, Han B, Rittmeyer A, Talbot T, Vicente D, Califano R, Cortinovis D, Le AT, Huang D, Liu G, Cappuzzo F, Reyes Contreras J, Reck M, Palmero R, Mak MP, Hu Y, Morris S, Höglander E, Connors M, Biggane AM, Vollan HK, Peters S. Lee SM, et al. Lancet. 2023 Aug 5;402(10400):451-463. doi: 10.1016/S0140-6736(23)00774-2. Epub 2023 Jul 6. Lancet. 2023. PMID: 37423228 Clinical Trial.
These data support atezolizumab monotherapy as a potential first-line treatment option for patients with advanced NSCLC who are ineligible for platinum-based chemotherapy. FUNDING: F Hoffmann-La Roche and Genentech Inc, a member of the Roche group....
These data support atezolizumab monotherapy as a potential first-line treatment option for patients with advanced NSCLC who are ineligible f …
Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.
McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, Koyama A, Irizarry M, Kramer LD, Bateman RJ. McDade E, et al. Alzheimers Res Ther. 2022 Dec 21;14(1):191. doi: 10.1186/s13195-022-01124-2. Alzheimers Res Ther. 2022. PMID: 36544184 Free PMC article. Clinical Trial.
13,916 results
You have reached the last available page of results. Please see the User Guide for more information.